BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25192879)

  • 1. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
    Boyle J; Craciunescu O; Steffey B; Cai J; Chino J
    Gynecol Oncol; 2014 Nov; 135(2):239-43. PubMed ID: 25192879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
    Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
    Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
    Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation study.
    Macchia G; Cilla S; Deodato F; Legge F; Di Stefano A; Chiantera V; Scambia G; Valentini V; Morganti AG; Ferrandina G
    Br J Radiol; 2015; 88(1055):20150385. PubMed ID: 26388108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
    Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes.
    Jouglar E; Thomas L; de la Rochefordière A; Noël G; Le Blanc-Onfroy M; Delpon G; Campion L; Mahé MA
    Cancer Radiother; 2016 Dec; 20(8):794-800. PubMed ID: 28270323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.
    Fonteyne V; Lumen N; Ost P; Van Praet C; Vandecasteele K; De Gersem Ir W; Villeirs G; De Neve W; Decaestecker K; De Meerleer G
    Radiother Oncol; 2013 Nov; 109(2):229-34. PubMed ID: 24016677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
    Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
    Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial.
    Macchia G; Cilla S; Deodato F; Ianiro A; Legge F; Marucci M; Cammelli S; Perrone AM; De Iaco P; Gambacorta MA; Autorino R; Valentini V; Morganti AG; Ferrandina G
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):606-13. PubMed ID: 27681755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.
    Vlacich G; Stavas MJ; Pendyala P; Chen SC; Shyr Y; Cmelak AJ
    Radiat Oncol; 2017 Jan; 12(1):13. PubMed ID: 28086954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose simultaneous integrated boost for node positive cervical cancer.
    Jayatilakebanda I; Tsang YM; Hoskin P
    Radiat Oncol; 2021 May; 16(1):92. PubMed ID: 34001158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up results of simultaneous integrated or late course accelerated boost with external beam radiotherapy to vaginal cuff for high risk cervical cancer patients after radical hysterectomy.
    Wang X; Zhao Y; Shen Y; Shu P; Li Z; Bai S; Xu F
    BMC Cancer; 2015 Apr; 15():257. PubMed ID: 25879580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost.
    McDonald MW; Godette KD; Whitaker DJ; Davis LW; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):523-30. PubMed ID: 19775834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
    Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis.
    Jung J; Park G; Kim YS
    Anticancer Res; 2014 Aug; 34(8):4361-6. PubMed ID: 25075072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.